MGMT Promoter Methylation Is Associated With Improved Survival in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial
JAMA Oncol 2018 Jun 28;[EPub Ahead of Print], EH Bell, P Zhang, BJ Fisher, DR Macdonald, JP McElroy, GJ Lesser, J Fleming, AR Chakraborty, Z Liu, AP Becker, D Fabian, KD Aldape, LS Ashby, M Werner-Wasik, EM Walker, JP Bahary, Y Kwok, HM Yu, NN Laack, CJ Schultz, HJ Gray, HI Robins, MP Mehta, A ChakravartiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.